Vaxcyte PCVX Stock
Vaxcyte Price Chart
Vaxcyte PCVX Financial and Trading Overview
| Vaxcyte stock price | 64.69 USD |
| Previous Close | 68.62 USD |
| Open | 67.6 USD |
| Bid | 48.24 USD x 200 |
| Ask | 83.3 USD x 200 |
| Day's Range | 64.62 - 67.6 USD |
| 52 Week Range | 42.4 - 90.75 USD |
| Volume | 1.07M USD |
| Avg. Volume | 2.17M USD |
| Market Cap | 10.24B USD |
| Beta (5Y Monthly) | 1.289 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.05 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 116.4 USD |
PCVX Valuation Measures
| Enterprise Value | 9.79B USD |
| Trailing P/E | N/A |
| Forward P/E | -9.767684 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.8799257 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -8.107 |
Trading Information
Vaxcyte Stock Price History
| Beta (5Y Monthly) | 1.289 |
| 52-Week Change | 50.64% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 90.75 USD |
| 52 Week Low | 42.4 USD |
| 50-Day Moving Average | 62.13 USD |
| 200-Day Moving Average | 57.58 USD |
PCVX Share Statistics
| Avg. Volume (3 month) | 2.17M USD |
| Avg. Daily Volume (10-Days) | 1.73M USD |
| Shares Outstanding | 158.3M |
| Float | 145.89M |
| Short Ratio | 4.16 |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 112.06% |
| Shares Short | 15.36M |
| Short % of Float | 9.81% |
| Short % of Shares Outstanding | 9.76% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.98% |
| Return on Equity (ttm) | -42.67% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -1207853056 USD |
| Net Income Avi to Common (ttm) | -1148493056 USD |
| Diluted EPS (ttm) | -8.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.29B USD |
| Total Cash Per Share (mrq) | 8.16 USD |
| Total Debt (mrq) | 221.84M USD |
| Total Debt/Equity (mrq) | 8.91 USD |
| Current Ratio (mrq) | 4.564 |
| Book Value Per Share (mrq) | 16.673 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -962009024 USD |
| Levered Free Cash Flow (ttm) | -529822752 USD |
Profile of Vaxcyte
| Country | United States |
| State | CA |
| City | San Carlos |
| Address | 825 Industrial Road |
| ZIP | 94070 |
| Phone | 650 837 0111 |
| Website | https://vaxcyte.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 507 |
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Q&A For Vaxcyte Stock
What is a current PCVX stock price?
Vaxcyte PCVX stock price today per share is 64.69 USD.
How to purchase Vaxcyte stock?
You can buy PCVX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vaxcyte?
The stock symbol or ticker of Vaxcyte is PCVX.
Which industry does the Vaxcyte company belong to?
The Vaxcyte industry is Biotechnology.
How many shares does Vaxcyte have in circulation?
The max supply of Vaxcyte shares is 158.3M.
What is Vaxcyte Price to Earnings Ratio (PE Ratio)?
Vaxcyte PE Ratio is now.
What was Vaxcyte earnings per share over the trailing 12 months (TTM)?
Vaxcyte EPS is -8.05 USD over the trailing 12 months.
Which sector does the Vaxcyte company belong to?
The Vaxcyte sector is Healthcare.
Vaxcyte PCVX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3026.97 USD — |
-1.72
|
— — | 3024.87 USD — | 3065.71 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12491.48 USD — |
-0.35
|
— — | 12339.28 USD — | 12603.6 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7247.55 USD — |
-2.3
|
— — | 7246.35 USD — | 7373.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
2341.48 USD — |
-0.98
|
— — | 2341.48 USD — | 2368.74 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
